Augustine Therapeutics Secures $84.2M Series A to Fuel Innovative CMT and Neurological Disorder Therapies

Augustine Therapeutics is excited to announce a significant milestone in its journey toward addressing unmet medical needs. The company, renowned for its pioneering research and commitment to developing innovative therapies, has successfully raised 84,200,000 dollars in its latest funding round. This robust financial backing will empower Augustine Therapeutics to accelerate its ambitious research and development programs aimed at discovering and advancing novel treatments for patients suffering from Charcot-Marie-Tooth disease (CMT) and other peripheral neuropathies, neurodegenerative, and cardiometabolic disorders. Rooted in the ground-breaking scientific contributions from esteemed institutions such as VIB and KU Leuven, Augustine Therapeutics leverages a strong foundation of academic excellence and cutting-edge biomedical research. The funding will not only enhance preclinical and clinical research initiatives but also support the optimization of drug delivery systems and further collaborations with partners who share the vision of transforming patient care. Endorsed by a distinguished cadre of supporters including Asabys Partners, Eli Lilly and Company, V-Bio Ventures, PMV, AdBio Partners, VIB, Gemma Frisius Fund, and the CMT Research Foundation, the company is well-positioned to redefine treatment pathways and improve outcomes for individuals affected by these debilitating conditions. This investment is a testament to the confidence placed in Augustine Therapeutics' scientific strategy and its commitment to delivering tangible benefits to patients, while also reinforcing robust practices in innovation and transparency. As the company embarks on its next phase of growth, it remains dedicated to its mission of transforming therapeutic landscapes and providing hope to patients worldwide.